To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. There is also limited clinical evidence for its utility in treatment of invasive disease caused by Fusarium species (fusariosis). Two studies published in the January 25, 2007 issue of the New England Journal of Medicine suggest posaconazole may be superior to other triazoles, such as fluconazole or itraconazole, in the prevention of invasive fungal infections, although it may cause more serious side effects.
Additional recommended knowledge
Posaconazole is marketed in the U.S. by Schering-Plough under the trade name Noxafil.
Can cause very severe kidney problems in otherwise healthy young individuals within days of starting course.
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Posaconazole". A list of authors is available in Wikipedia.|